Cargando…

An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses – A meeting report

The 12th HPV Prevention and Control meeting was held on June 2–3, 2022, in Antwerp, Belgium. This technical meeting focused on several topics. This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waheed, Dur-e-Nayab, Burdier, F. Ricardo, Eklund, Carina, Baussano, Iacopo, Mariz, Filipe Colaço, Téblick, Laura, Mugo, Nelly, Watson-Jones, Deborah, Stanley, Margaret, Baay, Marc, Vorsters, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480621/ https://www.ncbi.nlm.nih.gov/pubmed/37680853 http://dx.doi.org/10.1016/j.pmedr.2023.102368

Ejemplares similares

Prevention and control of HPV and HPV-related cancers in France: the evolving landscape and the way forward – a meeting report
por: Waheed, Dur-e-Nayab, et al.
Publicado: (2023)

HPV prevention and control – The way forward
por: Vorsters, Alex, et al.
Publicado: (2022)

Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report
por: Vorsters, Alex, et al.
Publicado: (2020)

Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives
por: Guillaume, Dominique, et al.
Publicado: (2022)

Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: What works in the context of low-resource countries?
por: Waheed, Dur-E-Nayab, et al.
Publicado: (2023)

Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine
por: Pattyn, Jade, et al.
Publicado: (2020)

A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial
por: Baisley, Kathy J., et al.
Publicado: (2021)

Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report
por: Waheed, Dur-e-Nayab, et al.
Publicado: (2021)

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial
por: Baisley, Kathy, et al.
Publicado: (2022)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
por: Khoury, David S., et al.
Publicado: (2023)

Building resilient cervical cancer prevention through gender-neutral HPV vaccination
por: Man, Irene, et al.
Publicado: (2023)

Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study
por: Baussano, Iacopo, et al.
Publicado: (2017)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Access and Attitudes to HPV Vaccination amongst Hard-To-Reach Populations in Kenya
por: Watson-Jones, Deborah, et al.
Publicado: (2015)

Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2
por: Mariz, Filipe Colaco, et al.
Publicado: (2023)

Comparison of a VLP‐based and GST‐L1‐based multiplex immunoassay to detect vaccine‐induced HPV‐specific antibodies in first‐void urine
por: Pattyn, Jade, et al.
Publicado: (2020)

The use of urine in the follow-up of HPV vaccine trials
por: Vorsters, Alex, et al.
Publicado: (2015)

Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void Urine
por: Téblick, Laura, et al.
Publicado: (2021)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing
por: Vorsters, Alex, et al.
Publicado: (2016)

Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan
por: Tshomo, Ugyen, et al.
Publicado: (2017)

Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme
por: Tshomo, Ugyen, et al.
Publicado: (2014)

Knowledge on HPV Vaccine and Cervical Cancer Facilitates Vaccine Acceptability among School Teachers in Kitui County, Kenya
por: Masika, Moses Muia, et al.
Publicado: (2015)

Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan
por: Baussano, Iacopo, et al.
Publicado: (2021)

Cervical cancer screening in rural Bhutan with the careHPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan)
por: Baussano, Iacopo, et al.
Publicado: (2017)

An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay
por: Torales, Julio, et al.
Publicado: (2023)

Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme
por: Ngabo, Fidele, et al.
Publicado: (2016)

HPV vaccination in Kenya: a study protocol to assess stakeholders' perspectives on implementation drivers of HPV vaccination and the acceptability of the reduced dose strategy among providers
por: Umutesi, Grace, et al.
Publicado: (2023)

Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR
por: Arroyo Mühr, Laila Sara, et al.
Publicado: (2020)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature
por: Pattyn, Jade, et al.
Publicado: (2019)

Prevention is life- and cost-saving
por: Baussano, Iacopo, et al.
Publicado: (2020)

Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study
por: Arroyo Mühr, Laila Sara, et al.
Publicado: (2022)

Options for design of real-world impact studies of single-dose vaccine schedules
por: Franceschi, Silvia, et al.
Publicado: (2018)

Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial
por: Elfström, K Miriam, et al.
Publicado: (2014)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

Detection of HPV and the role of p16(INK4A )overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
por: Morrow, Matthew P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4eqi1fnmf56e3un7jejdjo9csc